LinkedIn thought leader ad examples

J’avais 8 ans, au Brésil, quand un livre sur Louis Pasteur m’a donné un rêve : devenir chercheuse à l’Institut Pasteur. Des années plus tard, j’ai franchi les portes de l’Institut Pasteur. Aujourd’hui, j’accompagne celles et ceux qui font la science au quotidien, pour que chacun et chacune y trouve sa place. Mon parcours est né d’une confiance. Le Pasteurdon, c’est cette même confiance, offerte à la recherche. Depuis 20 ans, il permet à des chercheuses et chercheurs de poursuivre leurs idées et de préparer les découvertes de demain. 👉 Faire un don : https://lnkd.in/eaZ9C6Vx Vos dons protègent la recherche, la recherche protège la vie. #Pasteurdon #InstitutPasteur #Recherche #Science @Institut Pasteur

FUTURE FACES in Paris! Wir starten direkt mit einem Highlight. 🇫🇷 Ende Januar trifft sich in Paris wieder ein ziemlich großer Teil unserer Branche zur IMCAS, einem der wichtigsten internationalen Kongresse für ästhetische Medizin. Für uns bei Merz beginnt die Woche dieses Mal schon einen Tag früher. Am 27. Januar 2027 freuen wir uns darauf, bei FUTURE FACES einige unserer Expertinnen und Experten aus Deutschland, Österreich und der Schweiz in Paris zusammenzubringen. Und ich freue mich wirklich auf diese Runde. Bei FUTURE FACES wollen wir Wissenschaft, Business und auch die ethischen Fragen unserer Branche betrachten und gemeinsam darauf schauen, was die Zukunft der ästhetischen Medizin prägen wird. Welche Chancen entstehen gerade, welche Verantwortung bringen sie mit sich und welche neuen Blickwinkel brauchen wir vielleicht auch? Wenn so viele kluge Köpfe an einem Ort sind, sollte man die Gelegenheit auch nutzen, offen miteinander zu diskutieren. Ich hoffe ehrlich gesagt auch, dass wir dabei nicht überall einer Meinung sein werden. 😉 Gerade die unterschiedlichen Erfahrungen und Sichtweisen machen solche Gespräche für mich interessant. Wir stecken gerade mitten in den Vorbereitungen und die Vorfreude steigt auf jeden Fall schon. Ein paar Details muss ich leider noch für mich behalten, mehr dazu aber bald. Erst FUTURE FACES, dann IMCAS. Paris wird Ende Januar intensiv. 😉

𝗧𝗵𝗲 𝗻𝗲𝘅𝘁 𝗯𝗶𝗴 𝘀𝘁𝗲𝗽 𝗶𝗻 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗶𝘀𝗻'𝘁 𝗷𝘂𝘀𝘁 𝗮𝗯𝗼𝘂𝘁 𝘄𝗵𝗮𝘁 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 𝗰𝗮𝗻 𝗮𝗰𝗵𝗶𝗲𝘃𝗲. 𝗜𝘁 𝗶𝘀 𝗮𝗯𝗼𝘂𝘁 𝗺𝗮𝗸𝗶𝗻𝗴 𝘁𝗵𝗮𝘁 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝘄𝗼𝗿𝗸 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀. Across three days of discussions at the World Health Summit on global health, innovation and collaboration, there was one consensus: scientific progress alone does not make healthcare systems more resilient. What matters is whether that progress reaches patients. I was particularly honoured to contribute to Daiichi Sankyo's session on 𝘞𝘰𝘮𝘦𝘯'𝘴 𝘏𝘦𝘢𝘭𝘵𝘩 𝘢𝘵 𝘵𝘩𝘦 𝘊𝘰𝘳𝘦 𝘰𝘧 𝘙𝘦𝘴𝘪𝘭𝘪𝘦𝘯𝘤𝘦. From my experience as a physician, I know that even the most promising medical advances can only make a difference when the conditions around care are right. In breast cancer, for example, we have made remarkable progress. Yet across Europe, significant disparities remain in screening, timely diagnosis, biomarker testing and access to innovative treatments. At the IFPMA roundtable on trust in science, we explored another dimension of the same challenge: 𝗧𝗿𝘂𝘀𝘁 𝗶𝘀 𝗻𝗼𝘁 𝗲𝗮𝗿𝗻𝗲𝗱 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝘀 𝗮𝗹𝗼𝗻𝗲. 𝗜𝘁 𝗴𝗿𝗼𝘄𝘀 𝘄𝗵𝗲𝗻 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲 𝘁𝗵𝗲𝗶𝗿 𝗯𝗲𝗻𝗲𝗳𝗶𝘁𝘀. For me, these discussions reinforced something fundamental: 𝘁𝗵𝗲 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆'𝘀 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗴𝗼𝗲𝘀 𝗯𝗲𝘆𝗼𝗻𝗱 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀. We also have a role to play in connecting science, policy and clinical practice – working with partners across the healthcare ecosystem to turn progress into better outcomes. Thank you to everyone who contributed to these important conversations, and to my Daiichi Sankyo colleagues for making our engagement possible.

We are at NVIDIA GTC (GPU Technology Conference) in Berlin, and today Dawn Health, NVIDIA Healthcare, Microsoft for Healthcare, and Merck Healthcare proudly announce a collaboration to redefine the future of Patient Support Programs (PSPs). The four-way collaboration, the first-of-its-kind within patient support services, is building a novel agentic care experience available to people living with chronic disease, one that is personalized to each patients individual disease state, with access to a nurse or healthcare provider whenever it is needed. Merck Healthcare brings the patient insights, clinical, and pharmaceutical expertise, NVIDIA the technologies and AI reasoning models, and Microsoft the Azure Cloud and AI services. Dawn Health leads product development, regulatory work, and the human-centred design of the patient-facing application on the Dawn Platform. Kimberly Powell, Vice President and General Manager, Healthcare at NVIDIA, will introduce this vision on today’s session, Turning AI Into the Infrastructure Advancing Human Health, happening at NVIDIA GTC, Berlin, at 2:30pm CEST. If you are at NVIDA GTC this week, or evaluating the future of your own patient support programs, I would love to have a chat. Link to the full announcement: https://lnkd.in/dwVGkk_p

Great few days at NVIDIA GTC Berlin, with insightful sessions and discussions on AI and especially in life sciences and healthcare. 🚀 A major highlight was announcing our strategic four-way collaboration between Dawn HealthDawn Health, Merck Healthcare, MicrosoftMerck Healthcare, Microsoft and NVIDIA to redefine Patient Support Programs through AI-enabled, personalised and scalable patient support. A great example of moving beyond AI potential to creating real value for patients and healthcare professionals. Great to share this milestone with Emre Ozcan, PhD, Alexander Mandix Hansen, Wesley Snijders, Johannes Munding, Jantje Rees, Cedric SteenbekeCedric Steenbeke, Nelly Tian CodeToSaveLives #NVIDIAGTC #HealthcareAI #PatientSupport #DigitalHealth

𝐔𝐰 𝐟𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐬𝐜𝐡𝐞 𝐤𝐥𝐚𝐧𝐭 𝐬𝐭𝐞𝐥𝐭 𝐬𝐭𝐞𝐞𝐝𝐬 𝐡𝐨𝐠𝐞𝐫𝐞 𝐞𝐢𝐬𝐞𝐧 𝐚𝐚𝐧 𝐮𝐰 𝐨𝐩𝐬𝐥𝐚𝐠𝐜𝐨𝐧𝐝𝐢𝐭𝐢𝐞𝐬. 𝐁𝐞𝐧𝐭 𝐮 𝐚𝐚𝐧𝐭𝐨𝐨𝐧𝐛𝐚𝐚𝐫 𝐜𝐨𝐦𝐩𝐥𝐢𝐚𝐧𝐭? Logistiek dienstverleners die farmaceutische producten opslaan of distribueren weten het: de eisen van opdrachtgevers nemen toe. Een URS, periodieke audits, rapportageverplichtingen en soms directe inzage in het temperatuurbewakingssysteem. Voor de QA-afdeling betekent dit een groeiende administratieve last, zeker als de onderliggende systemen die transparantie niet kunnen bieden. Wat wij in de praktijk zien, is dat wie niet aantoonbaar compliant is, steeds vaker te maken krijgt met kortere audit intervallen en aanvullende documentatieverzoeken. In het uiterste geval staat de opdracht zelf ter discussie. Maar er is ook een andere kant van dit verhaal. Logistiek dienstverleners die hun koudeketen realtime en volledig gevalideerd bewaken, onderscheiden zich op het moment dat het er echt toe doet: aan tafel bij een nieuwe opdrachtgever. Wat wij terughoren van onze klanten, is dat opdrachtgevers het als een groot pluspunt zien als de opdrachtnemer hier al serieus over heeft nagedacht. Dyzle EMS biedt de mogelijkheid om opdrachtgevers directe inzage te geven in gevalideerde temperatuurdata, volledig in te richten via gebruikersbeheer en autorisaties. Zo is transparantie geen inspanning maar een gegeven. Meer weten over wat Dyzle Services B.V. voor logistiek dienstverleners kan betekenen? Kijk op onze website. #GDP #koudeketen #temperatuurbewaking #logistiek #kwaliteitsborging

Validated AI for Pharma Summit happened a month ago. I keep coming back to the keynote from Chris Decker, CDISC; so informative and inspiring. Validated systems have to be audited at ease. You need to be able to trace back the AI decisions, with the clarity on data sources and versions used. Watch the full keynote on: https://lnkd.in/dWqQ2Anm

What has changed in statistical computing since 2024? In 2024, Caroline Phares and Pascal Bouquet spoke with SCE leaders at several large pharma companies as part of the Open SCE initiative. They shared the findings at PHUSE EU Connect 2024: https://lnkd.in/duKEeXuw Reading those findings again alongside our conversations with biometrics leaders this year, the shift is clear. In 2024, the discussion centered on SCE infrastructure: * Orchestration: planning and task allocation were largely managed in Excel, and there was a strong need for an integrated orchestration layer. Code management: this emerged as a critical area. Git was seen as too complex for statisticians, and companies were looking for a simpler interface. Open source: concerns about support, maintenance, governance and siloed efforts were still significant. * AI: mostly a future topic, such as drafting code or a table of contents from the SAP, or generating independent QC programs. In 2026, the starting point is different: * Open source: established in GxP work. R-based submissions have been filed, and at one large pharma company about 60% of standard TFLs are now produced in R. The question has moved from why to when and how. * AI: in use, but in narrow and well-controlled places. AI-generated ADaM code is used on live studies, and tools that take an SAP through to TLFs are close to production. * QC: the question has reversed. In 2024, AI was discussed as a way to generate independent QC. Today, teams are asking what should replace independent replication when AI writes part of the code. Integration: the main friction is no longer moving code or tasks, but moving the metadata and context that give the data its meaning. Some things have not changed. Excel is still widely used, and human oversight remains the main safeguard. In the next post, we will look at the trends emerging from this shift.

I’m very excited to partner with Patsnap and Ray Chohan. Patsnap has done a fantastic job of making clinical trial and patent data AI-ready. Unlike others who just add data as an MCP call to say they have it, we’ve built custom skills, data models, and pipelines to bring this data into unified scientific workflows. Combining it with our rich data ecosystem, our knowledge graph, and more than 40 models that cover the jobs to be done in research. This is why Emet is becoming the workhorse for the world's largest research organizations. https://lnkd.in/g_3jMuVy

Clinical evaluation is the most underestimated challenge in your MDR compliance journey. Most manufacturers focus heavily on QMS documentation and technical files. But it's your clinical evaluation that often becomes the bottleneck. Why? Because it requires both scientific rigor and regulatory precision. And notified bodies are scrutinizing this area more than ever before. The stakes are clear: insufficient clinical data means delayed market access or even rejection. So what does a compliant clinical evaluation actually look like? Here are 5 essential elements every MedTech leader needs to master: Clinical Evaluation Plan (CEP) ↳ This isn't just a document. It's your roadmap for success. ↳ Define specific endpoints that align with your intended purpose. ↳ Remember that vague objectives lead to undefined outcomes. Literature Review Strategy ↳ Simply collecting studies isn't enough anymore. ↳ You need a systematic search methodology with clear inclusion/exclusion criteria. ↳ Document why certain studies were rejected, auditors always ask this. Clinical Data Sufficiency ↳ "Sufficient" clinical data is subjective until you define it. ↳ Create a clear threshold for what constitutes adequate evidence. ↳ Pre-MDR data often falls short of current expectations. Post-Market Clinical Follow-Up (PMCF) ↳ This isn't optional. It's a fundamental part of your clinical evaluation. ↳ Notified bodies expect proactive data collection, not just passive surveillance. ↳ The days of "we have no complaints" as sufficient PMCF are long gone. Equivalence Justification ↳ The bar for equivalence has been raised significantly under MDR. ↳ You need access to technical documentation of equivalent devices. ↳ Without contractual agreements, equivalence claims are increasingly difficult to defend. Clinical evaluation isn't a one-time task. It's a continuous process throughout your device's lifecycle. The manufacturers who succeed are those who integrate clinical thinking from design phase through post-market surveillance. P.S. What's been your biggest challenge with clinical evaluations under MDR? ⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡ MedTech regulatory challenges can be complex, but smart strategies, cutting-edge tools, and expert insights can make all the difference. I'm Tibor, passionate about leveraging AI to transform how regulatory processes are automated and managed. Let's connect and collaborate to streamline regulatory work for everyone! #automation #regulatoryaffairs #medicaldevices

This World Breast Cancer Day, I’m proud to contribute to a discussion about something fundamental: ensuring patients have the information and support they need to explore their options. At IceCure Medical, we believe awareness is not complete without choice. Watch the video and join the conversation.

Breast cancer awareness is essential. But awareness alone isn’t enough. Patients also need opportunities to learn about their treatment options, ask questions and have meaningful conversations with their healthcare team. I believe informed decision-making should be at the heart of breast cancer care. Watch this video from IceCure MedicalMedical for different perspectives on what choice means in breast cancer care.

This week at AMWC in Dubai, from 21 to 23 October, Galderma is presenting eight scientific abstracts spanning our injectable aesthetics portfolio, alongside a symposium and six Meet-the-Expert sessions. The congress follows the recent approval in the UAE Sculptra for use on the body including the gluteal area, posterior thighs and décolletage. An international consensus panel of 11 experts will present guidance on combining treatments across these new indications. We will also share pooled phase III data for relabotulinumtoxinA in frown lines and crows feet, in both toxin-naïve and previously treated patients. Alongside the clinical data, we will present findings from our survey of more than 4,300 women across nine countries on menopause-related skin changes. As always, we have a powerful range of information to share -- all part of our journey towards becoming a dermatology powerhouse. At Galderma we firmly believe that progress in aesthetics is guided by science, experience and thoughtful clinical judgment, and that is the spirit we bring to Dubai, as we continue to build a dermatology powerhouse. #Galderma #DermatologyPowerhouse #InjectableAesthetics #AMWCDubai

Pour ses 20 ans, le #Pasteurdon célèbre « le lien » et voit encore plus grand ! Le #Pasteurdon, c’est le moment où nous nous rappelons que l’Institut Pasteur nous appartient à tous. En effet, avec ses 140 ans d’histoire, ses 10 Prix Nobel et sa recherche d’excellence dans tous les champs de la science biomédicale, l’Institut Pasteur dépend majoritairement de la générosité du public pour vivre et rester performant dans la compétition mondiale. Grâce aux dons, nous pouvons recruter les meilleures scientifiques au monde et les équiper des meilleures technologies. Et nous pouvons surtout rester libres de choisir nos recherches et de nous consacrer aux questions qui comptent : futures pandémies, impact du changement climatique sur la santé, compréhension de l’origine des cancers et des maladies du cerveau… Cette année, le #Pasteurdon a 20 ans. Pour cet anniversaire, nous avons voulu voir grand, renouveler les formats et surtout renforcer le lien entre la recherche et le public, à travers : 🔹 Un nouveau film de marque, « Le Lien », réalisé par Valentin Guiod et produit par BIRTH pour The Good Company avec la chanson « Cette guerre » de Ben Mazué, gracieusement cédée à l’Institut ; 🔹 Un nouveau parrain, Kyan Khojandi, qui met son talent et sa notoriété au service du #Pasteurdon, après Kad Merad et Julia Vignali ; 🔹 20 villes ambassadrices, dont Ville de Paris, Ville de Lyon et Ville de Bordeaux, qui relaient et soutiennent le #Pasteurdon localement ; 🔹 Des partenariats renforcés avec France Télévisions et Groupe TF1, notamment autour de la semaine du #Pasteurdon et du « Pasteurday » ; 🔹 Une soirée de prestige, ce jeudi 8 octobre à l’Institut Pasteur, animée par Julian Bugier, avec de nombreuses personnalités, dont Francoise Barre-Sinoussié-Sinoussi, Erik Orsenna, Marie NDiaye et Emmanuel Grégoire ; 🔹 Le « Pasteurday », le samedi 10 octobre 2026 à l’Institut Pasteur, une journée portes ouvertes pour faire découvrir aux enfants et aux familles les métiers de la recherche biomédicale et susciter des vocations ! Toutes ces nouveautés ont une même ambition : faire du #Pasteurdon un moment de mobilisation plus large, plus visible et plus proche de toutes et tous. Car la recherche ne peut avancer sans le soutien de la société, qui a besoin de comprendre, de partager et de soutenir la recherche. Un immense merci à toutes les équipes, tous les partenaires, toutes les personnalités, toutes les villes et, bien sûr, tous les donateurs qui font vivre cette mobilisation depuis 20 ans. 👉 Pour soutenir la recherche de l’Institut Pasteur : www.pasteurdon.fr Vos dons protègent la recherche. La recherche protège la vie. Merci et bravo à Charlyne Burban Charlotte Tanésie Mazel Elena Ioannou Antoine Cerf Mathieu Fortoul Kadidia Siméon Margot Provot Hervé Bichot Arnaud Galès Sacha Tembe Myriam Rebeyrotte Aurélien Coustillac Jeanne Fenouil et les équipes communication interne et du Centre de conférence ! https://lnkd.in/eYakNT-k

Looking forward to hosting Matti Kontsas from Hintsa Performance in our webinar "Finding a Sustainable Path to Performance"! Check out the event and sign up to attend on November 12th!

Hipp Health team is heading to Atlantic City for Autism New Jersey’s 44th annual conference on October 22-23. I’ll be there with Dawn Robinson and Shomarr Malone, and I’m looking forward to connecting with fellow ABA professionals. I love hearing what other teams are trying and what they’re learning along the way. If you’ve made a change that’s helped your clinicians or made life easier for families, come tell us about it. Those everyday wins are worth sharing. You can schedule time with us at the conference here: https://lnkd.in/eB7_sY57

“A couple of thousand.” That was Stefan Heitmeier's answer when I asked how many molecules his team tested with one question in mind: How do you find a medicine that could prevent secondary strokes? Kudos to the team for their relentless work in service of stroke patients. Watch the whole video on YouTube: https://lnkd.in/eCE8rd5z

Heb jij ooit het einde van een regenboog bereikt? 🌈 Afgelopen weekend heb ik het geprobeerd. Samen met Emma Hodel, Eva Leemkuil, Lori Gustafson en Lars van Putten fietsten wij voor Team Boehringer Ingelheim 500 kilometer van Zoutkamp naar Zoutelande tijdens de Coast2Coast Challenge van de Nierstichting. We kregen zo'n beetje alle Nederlandse weersomstandigheden cadeau: zon, regen, héél veel regen, en af en toe een prachtige regenboog. Na een nacht fietsen, weinig slaap en 500 kilometer in de benen was ik eerlijk gezegd best blij dat ik weer gewoon van mijn fiets af mocht stappen. Voor ons was dit een sportieve uitdaging van één weekend. Voor mensen met een nierziekte zijn behandelingen, beperkingen en onzekerheden vaak onderdeel van het dagelijks leven. Juist daarom ben ik trots op wat we samen hebben gedaan. Dankzij alle deelnemers, vrijwilligers, supporters, sponsors en donateurs haalde de Nierstichting dit jaar meer dan €280.000 op voor onderzoek en innovatie die kunnen bijdragen aan een betere toekomst voor nierpatiënten. Een groot compliment aan de Nierstichting voor de organisatie van dit bijzondere evenement. En dank aan Boehringer Ingelheim, trotse hoofdsponsor, voor de steun aan een initiatief dat letterlijk en figuurlijk mensen in beweging brengt. En de regenbogen? Soms zit de pot goud niet aan het einde van de regenboog, maar in wat je samen onderweg bereikt. Dank aan iedereen die heeft gedoneerd, aangemoedigd of meegeleefd. Jullie maakten de kilometers een stuk lichter. Welke uitdaging heb jij ooit onderschat, maar achteraf voor geen goud willen missen? #Coast2Coast #Nierstichting #BoehringerIngelheim #CyclingForACause #Niergezondheid

Four years ago, Everlab had no members, one clinician and a very long to do list. This week, LinkedIn ranked us #2 on its Top Startups list for Australia. Since we started, we’ve grown to a team of 130, delivered 23x revenue growth in 2025 and raised a $65M Series A. Lists like this tend to reward pace. What I’m prouder of is where that pace has gone: 20,000+ members, 40,000+ consultations and 21m+ biomarker results, each one helping someone act on their health earlier. Healthcare is still overwhelmingly reactive and we're spending enormous amounts treating disease once it shows up. We started Everlab to do it the other way round. Start with the person, and work out what they need from there. It isn’t the easiest industry to operate in. Scaling healthcare means getting clinicians, technology, operations and member experience to move at the same speed, without ever trading off the quality of care. Most weeks, at least one of those is running ahead of the others. I’m incredibly grateful to the team building this every day. This recognition is a reflection of their work and the ambition we share. We’re actively hiring. Take a look at our careers page, or reach out if you think your skillset could be a fit for where we’re going.

Home care demand is growing, but that doesn't mean every market presents the same opportunity. I talk with agency owners every week who are making decisions about where to focus growth, where to recruit caregivers and how broadly to define their service area. Those decisions are much easier when they're grounded in actual market demand. Through millions of family interactions each year, A Place for Mom has unique insight into where families are searching for home care and how demand varies across markets. Our Home Care team can help you understand where families are actively searching for care and where opportunities for growth may exist in your market. If you're evaluating where to focus next, were happy to take a look at your market with you. Request a complimentary territory analysis: https://lnkd.in/gyds6JSs

Viimeisten kuukausien aikana olemme nostaneet esiin läheisten kokemuksia ja tarinoita siitä, miltä hoivan saatavuuden haasteet tuntuvat. Kasvoina kampanjassamme ovat olleet aidot läheiset, joilla on rakkaita meidän kodeissamme. Miksi pelkkiä naisia, minulta on kysytty. Eivätkö miehet muka pidä huolta läheisistään? Omaishoitajaliitto teki muutama vuosi takaperin kyselyn, johon vastasi lähes 2000 ihmistä. Vastanneista 4/5 oli naisia. Omaishoidon tukea saavista vastaajista 84 prosenttia oli naisia. Ilman omaishoidon tukea olevista vastaajista lähes yhdeksän kymmenesosaa oli naisia. Kun avun tarve on suurin ja sitovin, naiset kantavat vastuun. Valmistautuessamme kampanjaan, toteutimme sadoille valtakunnallisiin läheisteniltoihin osallistuneille kyselyn arjesta ennen hoivaan pääsyä. Sen pohjalta olimme yhteydessä noin 60 halukkaaseen läheiseen suoraan ja henkilökohtaisesti. Yhdeksän kymmenestä näistä oli naisia. Hoivalla on naisen kasvot. Ei sillä, tämä oli itselleni selvää jo ennen nykyistä työtänikin. Mutta nyt se on käynyt viimeistään selväksi. Puhuttiinpa sitten kotona tai hoivakodissa tapahtuvasta hoivasta.

Sama matka, mutta erilainen tarina 🩵 Attendo-kotien ikäihmisten läheisten rooli on saanut keskusteluissa ansaitsemaansa huomiota. Mutta pitkä matka kotiin ei kosketa vain heitä. Tällä kertaa tarinan kertoo Ulla, mielenterveys- ja päihdekuntoutujan läheinen. Sairaus voi pakottaa ihmisen jättämään kotinsa nopeasti. Läheinen joutuu oppimaan kaiken kerralla. Näin kävi kuvassa olevalle Ullalle, joka on 65-vuotias mielenterveys- ja päihdekuntoutujan sisko, läheinen ja edunvalvoja. Hän kertoo, että raskainta oli tutustua siskon sairauteen. Ullan sanat videollamme jäivät mieleeni: “Kyllä mä tämän jaksoin, koska oli sisko kyseessä.” Mielenterveys- ja päihdeongelmat koskettavat monia perheitä, mutta läheisistä puhutaan vähän. He opettelevat uusia rooleja, kantavat jatkuvaa huolta ja hoitavat asioita, joihin kukaan ei ole heitä valmentanut. Usein he tekevät sen yksin. Attendo-kodissa ammattilaiset kantavat arjen, jonka tavoitteena on toipuminen ja jaloilleen pääseminen - ja Ulla saa olla taas sisko. Kun läheinen saa tukea, hän jaksaa kulkea rinnalla pidempään. Hän jaksaa kannatella myös omaa arkeaan: työtä, perhe-elämää, vapaaehtoistoimintaa, mitä arki kullekin on! Toivomme, että päättäjät huomioisivat läheiset aina, kun he päättävät palveluista. Siksi olemme nostaneet tänä syksynä läheiset keskiöön. Pitkä matka kotiin – se tiivistää hyvin. Kerromme läheisten tarinoita, koska heidän matkansa alkaa pitkältä ennen kuin asukas muuttaa Attendo-kotiin. Ullan matka on yksi niistä. 💙 #EnnenKaikkeaOlemmeKoti @AttendoSuomi

To become a medical doctor🩺 , you need to study. A lot. Every doctor you meet has spent countless hours reading, questioning, and staying curious. When I was a young medical student, I believed all that studying was leading to one destination: working in a hospital, seeing patients every day, wearing the white coat. That was my path, and I had never questioned it. But life has serendipitous ways, and I ended up working in pharmacovigilance, far away from the hospital setting I had always envisioned for myself. While it was far from what I had expected, it broadened my perspective on what it means to care for patients. Over time, I realised that helping patients can take many forms and that not a single second of my medical training had been wasted. And this is #UncommonByNature: having the courage to challenge your own expectations, adapt to unexpected turns, and discover that your purpose can remain exactly the same even when your path changes completely. Pharmacovigilance may not be the most talked-about field in medicine, but it is essential. Most people will never see the work we do behind the scenes. Yet every case reviewed, every signal assessed, every risk understood, and every action taken have the same purpose: patient safety. World Patient Safety Day was a good reminder of that. For those of us working in pharmacovigilance, though, patient safety is not only a campaign or a date on the calendar. It is what we do every day and our way of caring for patients, even if we never meet them face to face. Working at Almirall has strengthened my conviction that real impact starts with a strong sense of purpose. By keeping patients at the heart of everything we do, we share a commitment that makes our work significant every day. Looking back, I no longer regret that my career did not follow the route I had planned. It taught me that there is more than one way to make a difference, and that meaning is not defined by a particular role, setting, or career path. I suspect many of us have similar stories. Stories of careers that didn't go exactly as planned, of unexpected turns that ultimately led us to where we were meant to be. And if you're considering a different route, joining a new company, or stepping into a role you never imagined for yourself, do not be afraid of the unexpected. Sometimes the opportunities that seem furthest from the plan are the ones that feel most meaningful in the end. If this speaks to you, Almirall could be the right fit #CareersAtAlmirall. Our team is growing: https://lnkd.in/e4EptByR

Soy una persona curiosa. Siempre lo he sido. Y tengo la suerte de formar parte de un entorno que alimenta esa curiosidad. La veo en las preguntas que nos hacemos cada día. En conversaciones que te llevan a replantearte una idea. En proyectos donde los datos acaban cambiando el plan previsto. Es una forma de pensar con la que me identifico mucho. Por eso #UncommonByNature tiene tanto sentido para mí. Lo relaciono con esa inquietud por entender un poco más. Con enfocar una hipótesis desde otro ángulo. Con atreverte a explorar cuando todavía no sabes cuál será el resultado. Creo que eso explica por qué disfruto tanto trabajando cerca de la ciencia y la innovación. Y también por qué, de vez en cuando, mi cabeza encuentra conexiones “curiosas”… incluso cuando cambio el ordenador por las botas de montaña. 🏔️🫣📽️ Si tú también disfrutas buscando respuestas y explorando hasta dónde pueden llevarte, echa un vistazo a las oportunidades que tenemos abiertas en Almirall. 👉 Descúbrelas aquí: https://lnkd.in/e5afbsG3 #Explore #Innovation #Pharma #WeAreAlmirall #UncommonByNature #CareersAtAlmirall